HGF has been shown to have angiogenetic properties and, based on animal experiments, is believed to have axon extension activity and show neuroprotective effects.
Kringle Pharma news release, June 16, 2014
Kringle Pharma starts phase I/II study on recombinant hepatocyte growth factor (HGF) protein for treatment of patients with spinal cord injury